Filing Flows › Caribou Biosciences (CRBU) › Q2 2026 › vs Q2 2025
Caribou Biosciences (CRBU) Q2 2026 vs Q2 2025 (year over year)
Caribou Biosciences's revenue fell $1.2M (-44%) from $2.7M in Q2 2025 to $1.5M in Q2 2026.
Caribou Biosciences, Q2 2026: revenue $1.5M (-44% year over year), net loss $24.3M, operating cash flow −$22.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.5M | $2.7M | −$1.2M | -44% |
| Other income, net | $1.1M | −$6.5M | $7.6M | — |
| Net loss | $24.3M | $54.1M | −$29.8M | -55% |
| Costs & expenses | $26.8M | $56.8M | −$29.9M | -53% |
| Operating costs | $26.8M | $50.2M | −$23.4M | -47% |
| Research & development | $18.9M | $27.7M | −$8.8M | -32% |
| General & admin | $7.9M | $10.4M | −$2.5M | -24% |
| Operating cash sources | $25.9M | $32.6M | −$6.7M | -20% |
| Depreciation & amortization | $625K | $1.2M | −$542K | -46% |
| Share-based compensation | $2.5M | $3.1M | −$652K | -21% |
| Cash used in operations | $22.8M | $28.3M | −$5.5M | -19% |
| Net loss absorbed | $24.3M | $54.1M | −$29.8M | -55% |
| Working capital & other | $1.6M | −$21.5M | $23.2M | — |
Questions
How much did Caribou Biosciences's revenue grow year over year in Q2 2026?
Caribou Biosciences's revenue fell $1.2M (-44%) from $2.7M in Q2 2025 to $1.5M in Q2 2026.